WuXi Biologics partners with HanchorBio on next-gen immunotherapies
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
List view / Grid view
The CRDMO will support the biotech company’s work on next-generation immunotherapies for oncology and autoimmune diseases.
Here, Alan Nafiiev, CEO and founder of Receptor.AI, discusses the benefits of using large language models to integrate literature evidence and structural prediction to accelerate binding site identification.
The impurities research illustrates an approach that could offer a simpler and more flexible downstream purification process.
CDMOs weigh up how to meet manufacturing demands across oral solid doses, monoclonal antibodies, ADCs and beyond.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
The new $5 billion manufacturing site is set to become the company’s first integrated facility for API and drug product manufacturing.
The novel AI-led approach could accelerate development of Alzheimer’s treatments by reducing related costs.
EPR Issue 2 includes articles on the impact of tariffs on the pharmaceutical supply chain, advances in bioprocessing, manufacturing and more.
The committee’s final draft guidance cited high-cost as a key reason for its negative opinion of the Alzheimer’s drugs, developed by Biogen and Eisai.
The method offers an alternative approach for efficient control in affinity chromatography as a separation technique, researchers propose.
The innovative device could improve CAR T cell cancer immunotherapy and facilitate its use as a first-line therapy, research suggests.
The biologic delivered sustained remission in adults with the inflammatory bowel disease (IBD) over the two-year study, results show.